Drugs / Tuvoraleimab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07514793 | Apr 2026 → Apr 2029 expected | mesothelioma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07347444 | Feb 2026 → Dec 2028 expected | acral lentiginous melanoma, mucosal melanoma | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tuvoraleimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07347444 ↗ |
| Route | Intravenous | “Iparomlimab and Tuvoraleimab: 5 mg/kg each, on Day 1, intravenous injection, every 3 weeks (Q3W);” NCT07514793 ↗ |